Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncoinvent ASACHIX:ONCINO 48 Cash Ratio is 2.24 as of Jun. 2026, which is 62% below its 10-year median of 5.86. GuruFocus rates CHIX:ONCINO with a GF Score™ of 48/100 and a GF Value™ of kr2,551.89. The stock has 5 warning signs investors should review. Among 1,382 Biotechnology companies, Oncoinvent ASA ranks worse than 56.3% on this metric.
Oncoinvent ASA (CHIX:ONCINo) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Oncoinvent ASA Cash Ratio Related Terms
Oncoinvent ASA Cash Ratio Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Cash Ratio of 2.24 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Oncoinvent ASA and its competitors. This is 62% below median its historical median of 5.86. Over the past decade, Oncoinvent ASA's Cash Ratio has ranged from 1.94 to 16.26. According to the industry distribution chart, Oncoinvent ASA ranks #778 out of 1382 companies in the Biotechnology industry, placing it in the top 56.3%.
Is Oncoinvent ASA's Cash Ratio too high?
Oncoinvent ASA's current Cash Ratio of 2.24 is 62% below median its 10-year median of 5.86. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 16.26. The Biotechnology industry median Cash Ratio is 2.95. Oncoinvent ASA's value of 2.24 is 23.9% below this industry median. Based on the distribution chart, Oncoinvent ASA ranks #778 out of 1382 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncoinvent ASA has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #778 out of 1382 companies for Cash Ratio. This places Oncoinvent ASA in the lower half of its industry. The industry median Cash Ratio is 2.95. Oncoinvent ASA's value of 2.24 is 23.9% below this benchmark. Historically, Oncoinvent ASA's own Cash Ratio has ranged from 1.94 to 16.26 over the past decade. While the company's 10-year median is 5.86 vs. the industry median of 2.95, Oncoinvent ASA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncoinvent ASA's current Cash Ratio of 2.24 is 23.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current Cash Ratio is 2.24, which is 62% below median its own 10-year median of 5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Cash Ratio of 2.24. The stock's GF Value™ is kr2,551.89, compared to a current price of kr1,039.91 — trading 59.2% below its estimated fair value. The current Cash Ratio is 2.24, which is 62% below median its 10-year median of 5.86 and 23.9% below the Biotechnology industry median of 2.95. Oncoinvent ASA's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Cash Ratio is 2.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 59.2% below its estimated GF Value™ of kr2,551.89.
Key valuation signals for CHIX:ONCINO:
Cash Ratio: 2.24 (62% below median its 10-year median of 5.86)
GF Value™: kr2,551.89 vs. price of kr1,039.91 (59.2% below fair value)
Industry Position: 23.9% below the Biotechnology median (#778 of 1382)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
48GF Score
Get the complete analysis for CHIX:ONCINO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
